GlaxoSmithKline Agrees to Pay $3 Billion in U.S. Drug Settlement

GlaxoSmithKline Plc (GSK) agreed to plead guilty and pay a $3 billion settlement to resolve criminal and civil charges linked to the company’s illegal promotion of prescription drugs and its failure to report safety data, according to a U.S. Justice Department statement today.

The agreement is the largest health-care fraud settlement in the U.S. and the largest payment by a drug company, the department said in the statement.

To contact the reporter on this story: Seth Stern in Washington at sstern14@bloomberg.net

To contact the editor responsible for this story: Justin Blum at jblum4@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.